APA (7th ed.) Citation

Grauer, S., Graf, R., Navarra, R., Sung, A., Logue, S., Stack, G., . . . Rosenzweig-Lipson, S. (2009). WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. Psychopharmacology, 204(1), 37. https://doi.org/10.1007/s00213-008-1433-z

Chicago Style (17th ed.) Citation

Grauer, Steven, et al. "WAY-163909, a 5-HT2C Agonist, Enhances the Preclinical Potency of Current Antipsychotics." Psychopharmacology 204, no. 1 (2009): 37. https://doi.org/10.1007/s00213-008-1433-z.

MLA (9th ed.) Citation

Grauer, Steven, et al. "WAY-163909, a 5-HT2C Agonist, Enhances the Preclinical Potency of Current Antipsychotics." Psychopharmacology, vol. 204, no. 1, 2009, p. 37, https://doi.org/10.1007/s00213-008-1433-z.